Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer - Reply

被引：1
|
作者：
Buzdar, AU [1 ]
Theriault, RL [1 ]
Hunt, KK [1 ]
Hortobagyi, GN [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 30期
关键词：
D O I：
10.1200/JCO.2005.03.2797
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7760 / 7761
页数：2
相关论文
共 50 条
  • [21] Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Pusztai, L
    Esteva, FJ
    CANCER INVESTIGATION, 2006, 24 (02) : 187 - 191
  • [22] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [23] Clinical utility of continuing trastuzumab beyond brain progression in HER-2-positive metastatic breast cancer -: Reply
    Gori, Stefania
    De Angelis, Verena
    Colozza, Mariantonietta
    Crino, Lucio
    ONCOLOGIST, 2007, 12 (12): : 1469 - 1471
  • [24] Docetaxel, Carboplatin and Trastuzumab (TCH) as Neoadjuvant (neoadj) Therapy in Patients (pts) with HER2-positive (HER2+) Operable Breast Cancer (BrCa)
    Zuradelli, M.
    Gullo, G.
    Walshe, J.
    Defrein, A. M.
    Healy, J.
    Kalachand, R.
    Murray, H.
    Sclafani, F.
    Crown, J. P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S177 - S177
  • [25] Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients
    Wu, Di
    Xiong, Liangfa
    ONCOLOGY LETTERS, 2020, 19 (03) : 2539 - 2546
  • [26] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [27] Mechanisms of resistance to trastuzumab as neoadjuvant therapy in women with HER2-overexpressing operable breast cancer.
    Jinno, Hiromitsu
    Sato, Tomomi
    Hayashida, Tetsu
    Takahashi, Maiko
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+operable breast cancer
    Blakely, L.
    Somer, B.
    Keaton, M.
    Hermann, R.
    Schnell, F.
    Cobb, P.
    Johns, A.
    Walker, M.
    Schwartzberg, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer
    Penault-Llorca, Frédérique
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Raoelfils, Inès
    Durando, Xavier
    Leheurteur, Marianne
    Gimbergues, Pierre
    Tortochaux, Jacques
    Curé, Hervé
    Chollet, Philippe
    ONCOLOGIST, 2007, 12 (04): : 390 - 396
  • [30] Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-Positive Human Breast Cancer Xenografts
    Francia, Giulio
    Man, Shan
    Lee, Chyan-Jang
    Lee, Christina R.
    Xu, Ping
    Mossoba, Miriam E.
    Emmenegger, Urban
    Medin, Jeffrey A.
    Kerbel, Robert S.
    CLINICAL CANCER RESEARCH, 2009, 15 (20) : 6358 - 6366
12345